CVS Caremark to put Zepbound back on formulary and add Foundayo

Effective Oct. 1, 2026, CVS Caremark will add Zepbound (tirzepatide) back to its commercial formularies as an additional preferred option. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo (orforglipron), an oral GLP-1 therapy. Both are Lilly’s products that are approved for weight loss.

CVS officials said in a news release this morning that Caremark has worked with Lilly to secure a more affordable cost.

For eligible patients with commercial coverage, both Zepbound and Foundayo are available for as little as $25 a month. Medicare Part D beneficiaries may also be eligible to pay $50 per month for their obesity medicines beginning July 1 through the Medicare GLP-1 Bridge program, a pilot program that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs. The Bridge program is a short-term CMS demonstration that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and Dec. 31, 2027.

CVS Caremark had dropped Zepbound in May 2025 in favor of Novo Nordisk’s Wegovy (semaglutide). Both Wegovy injection and pill will retain preferred status across CVS Caremark formularies. CVS Caremark patients currently on Wegovy can continue without interruption.

Caremark’s change in May 2025 led to a short increase in patients switching GLP-1 drugs before prescribing trends leveled off, according to Truveta data presented at the AMCP Annual Meeting in Nashville in April 2026.

Using data from Truveta, researchers analyzed two groups of patients: the first included adults ages 18 and older with a body mass index of 27 or higher who had two consecutive fills for a GLP-1 between January and September 2025. The second analysis examined prescribing trends for these drugs from January 2024 through September 2025, measuring each medication’s share of total prescriptions.

The overall study included 700,907 patients. It was found that before May 2025, switching from tirzepatide was low at about 0.6% per month, but it rose to 10.2% between June and July, marking a 17-fold increase.